New cocktail aims to boost remission in rare blood cancer

NCT ID NCT04624906

Ongoing Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) improves outcomes for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 63 participants will receive the three-drug combo for up to a year. The main goal is to see how many achieve a very good partial response or complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acalabrutinib (a targeted cancer drug) combined with bendamustine and rituximab (standard chemotherapy and immunotherapy)
What this could lead to: If successful, this combination could offer a more effective first-line treatment for Waldenstrom's macroglobulinemia, potentially leading to deeper and longer-lasting responses.
What could go wrong: This is a phase II trial with only 63 participants and no comparison group, so results are preliminary. The added drug (acalabrutinib) may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

CHU de Quebec - University Laval

Laval, Quebec, Canada
Cross Cancer Institute

Edmonton, Alberta, Canada
Hamilton Health Sciences Centre - Juravinksi

Hamilton, Ontario, Canada
McGill University Health Centre

Montreal, Quebec, Canada
QEII Health Sciences Centre

Halifax, Nova Scotia, Canada
Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada
The Ottawa Hospital

Ottawa, Ontario, Canada
Tom Baker Cancer Centre

Calgary, Alberta, Canada
Vancouver General Hospital

Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.